Prime Medicine, Inc. maintains a Buy rating, supported by an advancing prime editing pipeline and multiple upcoming clinical catalysts. Click for a PRME update.
Anthropic says Claude identified a novel enzyme system with characteristics reminiscent of CRISPR
CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader
Intellia Therapeutics (NasdaqGM:NTLA) said the FDA accepted its Biologics License Application for lonvo-z for hereditary angioedema. The agency granted Priority Review status, positioning lonvo-z as a
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity sca
View interactive chart, options flow, and AI analysis for NTLA on Zorveq Finance.
Open NTLA Chart & Analysis →